Lewati ke isi utama
  • Sign in
    Welcome !
    My account
    Logout

Lyra Therapeutics, Inc. (LYRA) Stock Forecast 2025 - AI Price Prediction & Analysis

Lyra Therapeutics, Inc. (LYRA) AI Stock Price Forecast & Investment Analysis

Lyra Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading Lyra Therapeutics, Inc. interactive price chart and technical analysis...

Lyra Therapeutics, Inc. (LYRA) - Comprehensive Stock Analysis & Investment Research

Company Overview & Business Profile

Lyra Therapeutics, Inc. (Stock Symbol: LYRA) is a leading company in the Industrial Applications and Services sector , specifically operating within the Surgical & Medical Instruments & Apparatus industry. The organization employs approximately 71 professionals worldwide . The company has established itself as an emerging investment opportunity with substantial growth potential.

Financial Performance & Key Metrics Analysis

Annual Revenue: $89 million generating a -106,1% net profit margin .

Market Capitalization: $524 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -89,3% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Advanced AI Stock Prediction & Price Target Analysis

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Lyra Therapeutics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Market Position & Competitive Advantage Analysis

Lyra Therapeutics, Inc. strategically competes in the highly dynamic Surgical & Medical Instruments & Apparatus marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities . The company maintains a healthy 2,0% gross margin, indicating strong pricing power and operational efficiency.

Lyra Therapeutics, Inc. (LYRA) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Lyra Therapeutics, Inc. stock analysis.

Loading Lyra Therapeutics, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Lyra Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Lyra Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Lyra Therapeutics, Inc.: With a P/E ratio of -0,12, the market sees the stock as potentially undervalued.

P/E Ratio -0,12x
P/B Ratio 135,20x
Market Cap $524M
EPS $-1,46
Book Value/Share $0,06
Revenue/Share $0,03
FCF/Share $-1,54
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Lyra Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Lyra Therapeutics, Inc.: An ROE of -89,3% indicates room for improvement in shareholder value creation.

ROE -89,3%
ROA -71,1%
ROIC -86,4%
Gross Margin 2,0%
Operating Margin -118,7%
Net Margin -106,1%
EBT Margin -755,9%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Lyra Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Lyra Therapeutics, Inc.: A current ratio of 2,28 indicates strong liquidity.

Current Ratio 2,28x
Quick Ratio 2,18x
D/E Ratio 0,01x
Financial Leverage 1,68x
Working Capital $71M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Lyra Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Lyra Therapeutics, Inc.: Free cash flow of $-32M indicates cash challenges that need attention.

Operating Cash Flow $-30M
Free Cash Flow $-32M
Capital Spending $-2M
FCF/Sales -574,2%
CapEx/Sales 41,0%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Lyra Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Lyra Therapeutics, Inc.: An asset turnover of 0,09x suggests room for improvement in asset utilization.

Asset Turnover 0,09x
Receivables Turnover 1,1x
Fixed Assets Turnover 1,1x
Days Sales Outstanding 323 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Lyra Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Lyra Therapeutics, Inc.: With annual revenue of $89M, Lyra Therapeutics, Inc. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $89M
Operating Income $-101M
Net Income $-42M
R&D Expense $50M
SG&A Expense $266M
Balance Sheet Highlights ($ Millions)
Total Current Assets $86M
Cash & Short-term Investments $71M
Total Liabilities $41M
Accounts Receivable $11M
Dividend & Shareholder Information
Shares Outstanding 66M
Growth Metrics (YoY)
EPS Growth -744,9%

Latest Lyra Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Lyra Therapeutics, Inc. (LYRA) stock price and investment outlook.

📰 We are currently updating our news feed for Lyra Therapeutics, Inc.. Check back soon for the latest market analysis and company updates.

Lyra Therapeutics, Inc. Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of Lyra Therapeutics, Inc. against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ADGM Unlock Forecast $25M x 2,9x
AEMD Unlock Forecast $3M -0,1x 0,7x
AFIB Unlock Forecast $0M 0,0x -0,4x
ALUR Unlock Forecast $17M -0,4x -0,3x
AMIX Unlock Forecast $4M x 0,5x
ANGO Unlock Forecast $421M -1,4x 2,3x
ANIK Unlock Forecast $135M -4,3x 0,9x
AORT Unlock Forecast $1911M -198,2x 4,6x
APYX Unlock Forecast $77M -3,5x 10,7x
ARAY Unlock Forecast $138M -9,9x 2,8x
ATEC Unlock Forecast $2333M -7,4x 98,2x
ATRC Unlock Forecast $1728M -39,6x 3,7x
AVGR Unlock Forecast $2M -1,3x 0,4x
AVHHL Unlock Forecast $20M x x
BAX Unlock Forecast $12055M -94,9x 1,7x
BBNX Unlock Forecast $855M x 2,8x
BDX Unlock Forecast $54739M 34,5x 2,2x
BEAT Unlock Forecast $46M -5,7x 11,0x
BEATW Unlock Forecast $15M x 3,2x
BJDX Unlock Forecast $2M -0,5x 0,4x
BLAC Unlock Forecast $12M x -2,1x
BLACR Unlock Forecast $1M x -0,2x
BLACU Unlock Forecast $14M x -2,4x
BLACW Unlock Forecast $0M x 0,0x
BSX Unlock Forecast $160575M 64,1x 7,2x
BTCY Unlock Forecast $10M -2,7x -0,1x
BVS Unlock Forecast $635M -18,3x 3,9x
CARL Unlock Forecast $-19M x x
CERS Unlock Forecast $235M -13,8x 4,2x
CLPT Unlock Forecast $298M -23,5x 15,1x
CODX Unlock Forecast $12M -0,7x 0,3x
CTCX Unlock Forecast $5M -0,2x -1,2x
CTCXW Unlock Forecast $1M x -0,2x
CTSO Unlock Forecast $64M -1,8x 4,4x
CVRX Unlock Forecast $205M -5,5x 3,5x
DCTH Unlock Forecast $440M 197,0x 4,2x
DHAI Unlock Forecast $10M x -0,3x
DHAIW Unlock Forecast $1M x 0,0x
DRIO Unlock Forecast $30M 0,6x 0,4x
DRTS Unlock Forecast $291M x 3,4x
DXCM Unlock Forecast $32184M 56,3x 12,5x
EBRCZ Unlock Forecast $246M x 5,0x
EMBC Unlock Forecast $572M 15,8x -0,8x
FEMY Unlock Forecast $12M -1,4x 7,7x
FNA Unlock Forecast $1098M -15,4x 8,4x
FOFA Unlock Forecast $9M x 17,0x
GCTK Unlock Forecast $2M 0,9x -0,5x
GIPL Unlock Forecast $5M x 27,9x
GKOS Unlock Forecast $5408M -46,3x 7,1x
GMED Unlock Forecast $8122M 22,8x 1,9x
GUTS Unlock Forecast $88M x 13,8x
HAE Unlock Forecast $3541M 26,1x 4,3x
HRGN Unlock Forecast $21M x 28,0x
IART Unlock Forecast $1125M 200,2x 1,1x
ICAD Unlock Forecast $106M -3,1x 3,5x
ICCM Unlock Forecast $66M x 22,7x
ICU Unlock Forecast $8M -1,1x 13,3x
ICUCW Unlock Forecast $0M x -0,1x
ICUI Unlock Forecast $3248M -49,8x 1,6x
IDXG Unlock Forecast $23M 4,5x -0,9x
IINN Unlock Forecast $28M x 6,5x
IINNW Unlock Forecast $8M x 1,8x
INBS Unlock Forecast $11M -0,3x 3,7x
INFU Unlock Forecast $229M 45,3x 4,2x
INSP Unlock Forecast $2609M 49,1x 3,9x
IRMD Unlock Forecast $903M 43,7x 9,6x
IRTC Unlock Forecast $5669M -20,2x 54,7x
IVF Unlock Forecast $1M x 0,3x
KIDS Unlock Forecast $499M -20,7x 1,4x
KMTS Unlock Forecast $829M x x
KRMD Unlock Forecast $195M -19,8x 11,8x
LMAT Unlock Forecast $0M 58,7x 0,0x
LNSR Unlock Forecast $59M -6,7x -7,0x
LUCD Unlock Forecast $128M -0,6x 16,3x
LUNG Unlock Forecast $70M -4,3x 1,0x
LYRA Unlock Forecast $524M -0,1x 135,2x
MBOT Unlock Forecast $92M -1,3x 3,2x
MCAG Unlock Forecast $22M x -9,6x
MCAGU Unlock Forecast $21M x -9,9x
MDAI Unlock Forecast $69M -1,3x -42,3x
MDAIW Unlock Forecast $9M x -2,1x
MDNC Unlock Forecast $59M 26,8x 13,4x
MDXG Unlock Forecast $1062M 33,0x 4,9x
MGRM Unlock Forecast $209M -10,7x 24,3x
MHUA Unlock Forecast $13M x 0,1x
MMM Unlock Forecast $83895M 21,3x 19,6x
MMSI Unlock Forecast $5491M 46,1x 3,7x
MODD Unlock Forecast $38M -2,1x 2,2x
NARI Unlock Forecast $4677M -51,9x 10,8x
NAYA Unlock Forecast $2M -0,3x 0,2x
NEPH Unlock Forecast $39M -20,3x 2,0x
NMTC Unlock Forecast $38M -1,7x 4,7x
NPCE Unlock Forecast $302M -10,4x 15,6x
NSPR Unlock Forecast $123M -4,3x 6,1x
NURO Unlock Forecast $9M -0,5x 0,7x
NVAC Unlock Forecast $69M 84,3x -13,6x
NVACR Unlock Forecast $1M x -0,1x
NVACW Unlock Forecast $0M x 0,0x
NVCR Unlock Forecast $1334M -20,8x 3,8x
NVNO Unlock Forecast $87M -2,0x 2,3x
NVRO Unlock Forecast $221M -2,1x 1,0x
NXGL Unlock Forecast $20M -6,8x 4,4x
NXGLW Unlock Forecast $3M x 0,7x
OBIO Unlock Forecast $118M -3,4x 2,0x
OFIX Unlock Forecast $591M -5,8x 1,3x
OSRH Unlock Forecast $26M x 0,3x
OSUR Unlock Forecast $247M 17,1x 0,7x
PAVM Unlock Forecast $22M 0,3x 0,6x
PAVMZ Unlock Forecast $0M x 0,0x
PDEX Unlock Forecast $158M 16,8x 4,5x
PEN Unlock Forecast $10576M 71,6x 8,2x
PETV Unlock Forecast $18M -1,4x 12,0x
PLSE Unlock Forecast $1016M -2,6x 8,6x
PODD Unlock Forecast $24267M 102,8x 16,6x
PRCT Unlock Forecast $2136M -45,4x 5,5x
PROF Unlock Forecast $134M x 3,4x
PSTV Unlock Forecast $12M -0,3x -0,5x
PYPD Unlock Forecast $52M x 2,6x
RCEL Unlock Forecast $115M -5,0x -29,9x
RDGL Unlock Forecast $51M x 18,9x
RMD Unlock Forecast $39665M 28,3x 6,7x
RSMDF Unlock Forecast $2450M 1,8x 0,4x
RTGN Unlock Forecast $66M x x
RVP Unlock Forecast $25M -0,9x 0,3x
SGHT Unlock Forecast $211M -3,7x 3,0x
SIBN Unlock Forecast $717M -14,3x 4,2x
SINT Unlock Forecast $7M -0,5x 1,1x
SKIN Unlock Forecast $292M -1,8x 4,0x
SNOA Unlock Forecast $7M -5,6x 1,8x
SNWV Unlock Forecast $357M x -19,4x
SOLV Unlock Forecast $12495M 32,9x 3,4x
SRDX Unlock Forecast $432M -79,3x 3,9x
SRTS Unlock Forecast $56M 31,6x 1,1x
SSII Unlock Forecast $1535M x 37,9x
SSKN Unlock Forecast $10M -8,0x 32,2x
STIM Unlock Forecast $256M -1,0x 9,4x
STME Unlock Forecast $12M x x
STSS Unlock Forecast $14M -2,5x 1,0x
STSSW Unlock Forecast $0M x 0,0x
SYK Unlock Forecast $140684M 42,0x 12,0x
TCMD Unlock Forecast $315M 20,9x 1,6x
TELA Unlock Forecast $81M -1,8x 8,8x
TFX Unlock Forecast $5687M 29,6x 1,3x
TLSI Unlock Forecast $191M -3,6x -5,6x
TLSIW Unlock Forecast $66M x -1,9x
TMCI Unlock Forecast $628M -7,5x 6,0x
TNDM Unlock Forecast $845M -17,1x 6,3x
TNON Unlock Forecast $9M -0,3x 1,4x
TNONW Unlock Forecast $0M x 0,0x
TTOO Unlock Forecast $4M 0,0x -0,3x
UFPT Unlock Forecast $1757M 44,7x 4,9x
USAQ Unlock Forecast $2M x x
UTMD Unlock Forecast $204M 16,2x 1,7x
VERO Unlock Forecast $5M 0,0x 2,1x
VTAK Unlock Forecast $3M 0,0x 0,3x
VVOS Unlock Forecast $21M -0,5x 2,8x
WST Unlock Forecast $18124M 37,2x 6,2x
XAIR Unlock Forecast $303M -0,3x 22,3x
XTNT Unlock Forecast $95M -478,8x 2,0x

Frequently Asked Questions - Lyra Therapeutics, Inc. Stock Forecast

How accurate are Lyra Therapeutics, Inc. stock predictions?

Our AI model demonstrates 17% historical accuracy for LYRA predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

What factors influence Lyra Therapeutics, Inc. stock price forecasts?

Our analysis considers Lyra Therapeutics, Inc.'s financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Lyra Therapeutics, Inc. a good investment in 2025?

Based on our AI analysis, Lyra Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Lyra Therapeutics, Inc. forecasts updated?

Lyra Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Lyra Therapeutics, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Lyra Therapeutics, Inc. stock.

🎯 Get Premium Analysis 📊 Explore More Stocks

My Portfolio

Investment Dashboard

Loading your portfolio...